dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Simó, Marta |
dc.contributor.author | Massuti, Bartomeu |
dc.contributor.author | Juan, Oscar |
dc.contributor.author | Huidobro, Gerardo |
dc.contributor.author | FELIP, ENRIQUETA |
dc.contributor.author | Nadal, Ernest |
dc.contributor.author | Rodriguez-Abreu, Delvys |
dc.date.accessioned | 2023-10-02T12:35:07Z |
dc.date.available | 2023-10-02T12:35:07Z |
dc.date.issued | 2023-10-01 |
dc.identifier.citation | Nadal E, Rodríguez-Abreu D, Simó M, Massutí B, Juan O, Huidobro G, et al. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05). J Clin Oncol. 2023 Oct 1;41(28):4478–85. |
dc.identifier.issn | 1527-7755 |
dc.identifier.uri | https://hdl.handle.net/11351/10396 |
dc.description | Atezolizumab; Càncer de pulmó de cèl·lules no petites; Metàstasi cerebral |
dc.language.iso | eng |
dc.publisher | American Society of Clinical Oncology |
dc.relation.ispartofseries | Journal of Clinical Oncology;41(28) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Pulmons - Càncer - Tractament |
dc.subject | Quimioteràpia combinada |
dc.subject | Metàstasi |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Drug Therapy, Combination |
dc.subject.mesh | Brain Neoplasms |
dc.title | Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05) |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1200/JCO.22.02561 |
dc.subject.decs | carcinoma de pulmón de células no pequeñas |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | farmacoterapia combinada |
dc.subject.decs | neoplasias cerebrales |
dc.relation.publishversion | http://dx.doi.org/10.1200/JCO.22.02561 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Nadal E] Department of Medical Oncology, Institut Català d’Oncologia (ICO), L'Hospitalet de Llobregat, Barcelona, Spain. Preclinical and Experimental Research in Thoracic Tumors (PReTT) Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. [Rodríguez-Abreu D] Department of Medical Oncology, Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain. [Simó M] Neuro-Oncology Unit, Hospital Universitari de Bellvitge-ICO, IDIBELL, L'Hospitalet, Barcelona, Spain. [Massutí B] Department of Medical Oncology, Hospital General de Alicante, Alicante, Spain. [Juan O] Department of Medical Oncology, Hospital Universitari La Fe, Valencia, Spain. [Huidobro G] Department of Medical Oncology, Complejo Hospitalario Universitario de Vigo, Vigo, Spain. [Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 37603816 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |